IPO Databook: Attovia Therapeutics (ATTO US) - Aug 2026

148 Views31 Jul 2026 10:17

SUMMARY

Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.
Attovia Therapeutics is a clinical-stage biopharmaceutical company with a proprietary ATTOBODY platform. Lead candidate ATTO-1310 completed Phase 1 dosing in Q1 2026.
As of June 30, 2026, Attovia had approximately $115.1 million in cash, cash equivalents, and marketable securities. Net loss for 2025 was $(60,627).

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream